Bicycle Therapeutics plc (BCYC) Cash Flow Statement

An operating cash flow to net income ratio above 1.0 in loss-making quarters indicates that cash outflows are not simply mirroring the reported loss, which warrants further investigation into working capital timing and non-cash items. Stock-based compensation of $5.4M to $10.3M per quarter is a material non-cash add-back, yet it does not explain the full gap, suggesting that working capital swings may be driving much of the variance. Investors should monitor whether this relationship normalizes as R&D spend declines or whether cash conversion remains structurally weak.

Negative free cash flow in every reported period, with CapEx consistently near zero in dollar terms, indicates that the burn is operating-driven rather than investment-driven. The sharp deterioration in the latest quarter appears tied to a $37.0M working capital outflow against minimal revenue, which may reflect timing effects that could reverse, though the data does not confirm this. The absence of a sustained improvement trend means investors should monitor whether burn rates moderate as collaboration revenue stabilizes.

Large alternating working capital movements without a consistent directional pattern suggest that collaboration receivables and payables timing is the primary driver of reported operating cash flow rather than core operating efficiency. The 2025Q4 inflow of $62.9M coincided with a deeply negative net loss, which implies cash generation from balance sheet timing rather than improved economics. Investors should monitor the collection pattern on collaboration receivables, since reliance on lumpy timing differences may not represent durable cash generation.

The absence of shareholder distributions is consistent with a company in an operating-loss profile, where capital preservation takes priority over returns. Without reported acquisition spending or debt paydown, the cash flow statement offers no evidence of capital being redeployed for growth or balance sheet optimization. The critical question for analysts is how the negative operating cash flow is funded, which requires examination of the balance sheet and financing disclosures beyond the scope of this cash flow data.